Why the study?
Does acute intravenous verapamil alter cardiovascular function in patients with and without ischemic heart disease?
Does acute intravenous verapamil alter cardiovascular function in patients with and without ischemic heart disease?
Acute intravenous verapamil is safe and does not depress myocardial contractility in patients with ischemic heart disease.
Answers are grounded in this paper and cite their sources.
Supports potential hemodynamic safety of acute IV verapamil in IHD without contractility depression; hypothesis-generating and leaves open need for randomized confirmation.
Alterations in cardiovascular function induced by the acute intravenous administration of verapamil (5 or 10 mg) in 52 patients (29 with ischemic heart disease and 23 without heart disease) were evaluated with use of invasive techniques (right and left heart catheterization, left ventricular cineangiography, and coronary arteriography). The most significant changes were represented by a decrease in systemic vascular resistance and systemic arterial pressure, and an increase in heart rate and cardiac output. Contractility indexes were not depressed in either group, and altered ventricular wall motion tended to improve to a slightly smaller degree than in patients treated with nitroglycerin. The use of verapamil in patients with ischemic heart disease appears to be safe, and concern about the negative inotropic influences in humans no longer seems justified.
No takes yet. Share an insight, caveat, or question.
Vincenzi et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: